User profiles for "author:Lorea Villanueva"

Lorea Villanueva Legarda

Centro de Investigación Médica Aplicada/Universidad de Navarra
Verified email at alumni.unav.es
Cited by 606

[HTML][HTML] The contribution of epigenetics to cancer immunotherapy

L Villanueva, D Álvarez-Errico, M Esteller - Trends in immunology, 2020 - cell.com
Effective anticancer immunotherapy treatments constitute a qualitative leap in cancer
management. Nonetheless, not all patients benefit from such therapies because they fail to …

Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and …

G Villacampa, P Tolosa, F Salvador… - Cancer Treatment …, 2022 - Elsevier
Introduction The addition of immune checkpoint inhibitors (ICI) to chemotherapy (CT) has
been one of the main clinical research endeavors over the last few years in patients with …

Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment?

JM Cejalvo, C Falato, L Villanueva, P Tolosa… - Cancer Treatment …, 2022 - Elsevier
Immunotherapy has revolutionized the oncology field during the last years, mainly with the
introduction of immune checkpoint inhibitors in the clinical routine. Despite the recent …

[HTML][HTML] Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma …

D Llopiz, M Ruiz, L Villanueva, T Iglesias… - Cancer Immunology …, 2019 - Springer
Immune checkpoint inhibitors are currently tested in different combinations in patients with
advanced hepatocellular carcinoma (HCC). Nivolumab, an anti-PD-1 agent, has gained …

Epigenetic profiling and response to CD19 chimeric antigen receptor T-cell therapy in B-cell malignancies

CA Garcia-Prieto, L Villanueva… - JNCI: Journal of the …, 2022 - academic.oup.com
Background Chimeric antigen receptor (CAR) T cells directed against CD19 (CART19) are
effective in B-cell malignancies, but little is known about the molecular factors predicting …

Inhibition of FOXP3/NFAT interaction enhances T cell function after TCR stimulation

T Lozano, L Villanueva, M Durántez… - The Journal of …, 2015 - journals.aai.org
Regulatory T cell (Treg) activity is modulated by a cooperative complex between the
transcription factor NFAT and FOXP3, a lineage specification factor for Tregs. FOXP3/NFAT …

[HTML][HTML] IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination

D Llopiz, M Ruiz, S Infante, L Villanueva, L Silva… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Vaccination induces immunostimulatory signals that are often accompanied by regulatory
mechanisms such as IL-10, which control T-cell activation and inhibit vaccine-dependent …

Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin

C Mansilla, P Berraondo, M Durantez… - … Journal of Cancer, 2012 - Wiley Online Library
Cervical carcinoma is one of the most common cancers in women worldwide. It is well
established that chronic infection of the genital tract by various mucosatropic human …

[HTML][HTML] Cold-inducible RNA binding protein as a vaccination platform to enhance immunotherapeutic responses against hepatocellular carcinoma

L Silva, J Egea, L Villanueva, M Ruiz, D Llopiz… - Cancers, 2020 - mdpi.com
Simple Summary Current immunotherapies based on blockade of immunosuppressive
elements provide limited results in liver cancer patients. Here we tested whether …

[HTML][HTML] DNA methylation-associated dysregulation of transfer RNA expression in human cancer

M Rosselló-Tortella, A Bueno-Costa, L Martínez-Verbo… - Molecular Cancer, 2022 - Springer
The human cytoplasmatic pool of tRNA for the 20 proteinogenic amino acids and
selenocysteine is composed of 48 isoacceptor families–those tRNA with different anticodons …